open access

Vol 21, No 1 (2018)
Original articles
Published online: 2017-10-11
Submitted: 2017-08-05
Accepted: 2017-10-06
Get Citation

Radiosynoviorthesis of acromioclavicular joint using 169Er-citrate: prospective evaluation of efficacy

Marika Vereb, Knut Liepe, Manfred Fischer, Lucia Kaliska, Lucia Noskovicova, Sona Balogova
DOI: 10.5603/NMR.a2018.0004
·
Pubmed: 29319135
·
Nucl. Med. Rev 2018;21(1):26-31.

open access

Vol 21, No 1 (2018)
Original articles
Published online: 2017-10-11
Submitted: 2017-08-05
Accepted: 2017-10-06

Abstract

BACKGROUND

There is a clinical need for therapeutic alternative in patients with persisting painful arthritis of AC-joint and failure of previous treatments. However, no radiopharmaceutical is currently explicitly approved for radiosynoviorthesis of acromioclavicular joint. The aim of our study was to prospectively assess the efficacy and safety of radiosynoviorthesis of acromioclavicular joint using erbium-169 citrate.

MATERIAL AND METHODS

Radiosynoviorthesis of acromioclavicular joint was performed in 51 consecutive patients (18 males, 33 females) mean age 64.3 (range 43.8–82.6, median 63.6) years with clinically confirmed arthritis of 85 acromioclavicular joints. The efficacy of RSO was reported by patients according to 10-step visual analogue scale of pain (VAS) (0 = no pain, 10 = most severe pain) at 6 months after radiosynoviorthesis and by ranking the global therapeutic effect of RSO in 4 categories (1 = the best effect, 4 = no change). To assess the variation of blood perfusion in treated joints, the efficacy of RSO was also evaluated by variation of target (acromioclavicular joint)/non-target (soft tissue) uptake ratio (T/NTR) of metylendiphosphonate (99mTc) measured as number of counts over region of interest on blood pool phase of two-phase bone scintigraphy performed before and 6 months after RSO.

RESULTS

Radiosynoviorthesis was followed by significant decrease in VAS, mean — 3.1 (-47%). Excellent, good, moderate and bad response was observed in 57 (67%), 25 (29%), 1 (1%) and in 2 (2%) of acromioclavicular joints respectively. A significant correlation between decrease of T/NTR and variation of VAS in % (ρ = 0.532, p < 0.0001) and between T/NTR and subjective evaluation of therapeutic effect in scale 1–4 (ρ = 0.388, p = 0.0002) was observed. However, it was not possible to identify the cut-off value of relative decrease in T/NTR showing sufficient sensitivity and specificity to detect the therapeutic response.

CONCLUSION

Results of this prospective study permit to conclude a good efficacy and safety of radiosynoviorthesis using erbium-169 citrate in a series of patients with arthritis of acromioclavicular joint in whom previous line(s) of treatment did not lead to satisfactory pain relief.

Abstract

BACKGROUND

There is a clinical need for therapeutic alternative in patients with persisting painful arthritis of AC-joint and failure of previous treatments. However, no radiopharmaceutical is currently explicitly approved for radiosynoviorthesis of acromioclavicular joint. The aim of our study was to prospectively assess the efficacy and safety of radiosynoviorthesis of acromioclavicular joint using erbium-169 citrate.

MATERIAL AND METHODS

Radiosynoviorthesis of acromioclavicular joint was performed in 51 consecutive patients (18 males, 33 females) mean age 64.3 (range 43.8–82.6, median 63.6) years with clinically confirmed arthritis of 85 acromioclavicular joints. The efficacy of RSO was reported by patients according to 10-step visual analogue scale of pain (VAS) (0 = no pain, 10 = most severe pain) at 6 months after radiosynoviorthesis and by ranking the global therapeutic effect of RSO in 4 categories (1 = the best effect, 4 = no change). To assess the variation of blood perfusion in treated joints, the efficacy of RSO was also evaluated by variation of target (acromioclavicular joint)/non-target (soft tissue) uptake ratio (T/NTR) of metylendiphosphonate (99mTc) measured as number of counts over region of interest on blood pool phase of two-phase bone scintigraphy performed before and 6 months after RSO.

RESULTS

Radiosynoviorthesis was followed by significant decrease in VAS, mean — 3.1 (-47%). Excellent, good, moderate and bad response was observed in 57 (67%), 25 (29%), 1 (1%) and in 2 (2%) of acromioclavicular joints respectively. A significant correlation between decrease of T/NTR and variation of VAS in % (ρ = 0.532, p < 0.0001) and between T/NTR and subjective evaluation of therapeutic effect in scale 1–4 (ρ = 0.388, p = 0.0002) was observed. However, it was not possible to identify the cut-off value of relative decrease in T/NTR showing sufficient sensitivity and specificity to detect the therapeutic response.

CONCLUSION

Results of this prospective study permit to conclude a good efficacy and safety of radiosynoviorthesis using erbium-169 citrate in a series of patients with arthritis of acromioclavicular joint in whom previous line(s) of treatment did not lead to satisfactory pain relief.

Get Citation

Keywords

radiosynoviorthesis, arthritis, acromioclavicular joint, 169Er-citrate, pain relief

About this article
Title

Radiosynoviorthesis of acromioclavicular joint using 169Er-citrate: prospective evaluation of efficacy

Journal

Nuclear Medicine Review

Issue

Vol 21, No 1 (2018)

Pages

26-31

Published online

2017-10-11

DOI

10.5603/NMR.a2018.0004

Pubmed

29319135

Bibliographic record

Nucl. Med. Rev 2018;21(1):26-31.

Keywords

radiosynoviorthesis
arthritis
acromioclavicular joint
169Er-citrate
pain relief

Authors

Marika Vereb
Knut Liepe
Manfred Fischer
Lucia Kaliska
Lucia Noskovicova
Sona Balogova

References (19)
  1. Soroa V, Espeche MV, Giannone C, et al. Effects of Radiosynovectomy with P-32 Colloid Therapy in Hemophilia and Rheumatoid Arthritis. Cancer Biotherapy & Radiopharmaceuticals. 2005; 20(3): 344–348.
  2. Bessant R, Steuer A, Rigby S, et al. Osmic acid revisited: factors that predict a favourable response. Rheumatology (Oxford). 2003; 42(9): 1036–1043.
  3. Knut L. Radiosynovectomy in the therapeutic management of arthritis. World J Nucl Med. 2015; 14(1): 10–15.
  4. Kraft O, Kašparek R. Effectiveness of radiosynoviorthesis in the treatment of chronic synovitis of small and middle-sized joints affected by rheumatoid arthritis. Hell J Nucl Med. 2011; 14(3): 251–254.
  5. Clunie G, Fischer M. EANM. EANM procedure guidelines for radiosynovectomy. Eur J Nucl Med Mol Imaging. 2003; 30(3): BP12–BP16.
  6. Bowring CS, Keeling DH. Absorbed radiation dose in radiation synovectomy. Br J Radiol. 1978; 51(610): 836–837.
  7. Noble J, Jones AG, Davies MA, et al. Leakage of radioactive particle systems from a synovial joint studied with a gamma camera. Its application to radiation synovectomy. The Journal of Bone & Joint Surgery. 1983; 65(3): 381–389.
  8. Kresnik E, Mikosch P, Gallowitsch HJ, et al. Clinical outcome of radiosynoviorthesis: a meta-analysis including 2190 treated joints. Nucl Med Commun. 2002; 23(7): 683–688.
  9. Gracely RH, McGrath F, Dubner R. Ratio scales of sensory and affective verbal pain descriptors. Pain. 1978; 5(1): 5–18.
  10. Liepe K. Efficacy of radiosynovectomy in rheumatoid arthritis. Rheumatology International. 2011; 32(10): 3219–3224.
  11. IBA_Molecular. 169Er-citrate Summary of Product Characteristics 2017. http://ibamolecular.com/wp-content/uploads/2017/02/P0500nE.pdf.
  12. Ruotsi A, Hypén M, Rekonen A, et al. Erbium--169 versus triamcinolone hexacetonide in the treatment of rheumatoid finger joints. Ann Rheum Dis. 1979; 38(1): 45–47.
  13. Zuderman L, Liepe K, Zöphel K, et al. Radiosynoviorthesis (RSO): influencing factors and therapy monitoring. Ann Nucl Med. 2008; 22(9): 735–741.
  14. van der Zant FM, Jahangier ZN, Moolenburgh JD, et al. Clinical effect of radiation synovectomy of the upper extremity joints: a randomised, double-blind, placebo-controlled study. Eur J Nucl Med Mol Imaging. 2007; 34(2): 212–218.
  15. Menkes CJ, Gô AL, Verrier P, et al. Double-blind study of erbium 169 injection (synoviorthesis) in rheumatoid digital joints. Ann Rheum Dis. 1977; 36(3): 254–256.
  16. Boussina I, Toussaint M, Ott H, et al. A double-blind study of erbium169 synoviorthesis in rheumatoid digital joints. Results after one year. Scand J Rheumatol. 1979; 8(2): 71–74.
  17. Kahan A, Mödder G, Menkes CJ, et al. 169Erbium-citrate synoviorthesis after failure of local corticosteroid injections to treat rheumatoid arthritis-affected finger joints. Clin Exp Rheumatol. 2004; 22(6): 722–726.
  18. Gumpel JM, Matthews SA, Fisher M. Synoviorthesis with erbium-169: a double-blind controlled comparison of erbium-169 with corticosteroid. Ann Rheum Dis. 1979; 38(4): 341–343.
  19. Manil L, Voisin P, Aubert B, et al. Physical and biological dosimetry in patients undergoing radiosynoviorthesis with erbium-169 and rhenium-186. Nucl Med Commun. 2001; 22(4): 405–416.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl